Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy

References

• Monteleone P, Mascagni G, Giannini A, et al. Symptoms of menopause—global prevalence, physiology and implications. Nat Rev Endocrinol. 2018;14(4):199–215.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass MLS, Kingsberg S, et al. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Climacteric. 2014;17(5):557–563.
   PubMed Web of Science ®Google Scholar
• Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75(6):988–1000.
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26.
   PubMed Web of Science ®Google Scholar
• Hanna-Mitchell AT, Robinson D, Cardozo L, et al. Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014. Neurourol Urodynam. 2016;35(2):299–303.
   PubMed Web of Science ®Google Scholar
• Bunn F, Kirby M, Pinkney E, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract. 2015;69(2):199–217.
   PubMed Web of Science ®Google Scholar
• Klausner AP, Steers WD. Corticotropin releasing factor: a mediator of emotional influences on bladder function. J Urol. 2004;172(6 Part 2):2570–2573.
   PubMedGoogle Scholar
• Schneeweiss J, Koch M, Umek W. The human urinary microbiome and how it relates to urogynecology. Int Urogynecol J. 2016;27(9):1307–1312.
   PubMed Web of Science ®Google Scholar
• Hubeaux K, Deffieux X, Ismael SS, et al. Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence. Journal of Urology. 2007;178(6):2483–2487.
   PubMed Web of Science ®Google Scholar
• Milsom I, Coyne KS, Nicholson S, et al. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95.
   PubMed Web of Science ®Google Scholar
• Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology. 2003;62(5 Suppl 2):28–37.
   PubMedGoogle Scholar
• Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause. Obstetr Gynecol. 2014;124(6):1147–1156.
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L, Milsom I, et al. Oestrogens and overactive bladder. Neurourol Urodynam. 2014;33(7):1086–1091.
   PubMed Web of Science ®Google Scholar
• Russo E, Caretto M, Giannini A, et al. Management of urinary incontinence in postmenopausal women: an EMAS clinical guide. Maturitas. 2020;143:223–230.
   PubMed Web of Science ®Google Scholar
• Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int. 2013;19(4):155–162.
   PubMedGoogle Scholar
• Palacios S. Ospemifene for vulvar and vaginal atrophy: an overview. DIC. 2020;9:1–5.
   Google Scholar
• Simon JA, Altomare C, Cort S, et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health. 2018;27:14–23.
   PubMed Web of Science ®Google Scholar
• Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61(3):508–516.
   PubMed Web of Science ®Google Scholar
• Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10(10):CD001405.
   PubMedGoogle Scholar
• Araklitis G, Baines G, da Silva AS, et al. Recent advances in managing overactive bladder. F1000Res. 2020;9:1125.
   Google Scholar
• Schiavi MC, Sciuga V, Giannini A, et al. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? Gynecol Endocrinol. 2018;34(8):666–669.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Zullo MA, Faiano P, et al. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol Endocrinol. 2017;33(12):942–945.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, D’Oria O, Aleksa N, et al. Usefulness of ospemifene in the treatment of urgency in menopausal patients affected by mixed urinary incontinence underwent mid-urethral slings surgery. Gynecol Endocrinol. 2019;35(2):155–159.
   PubMed Web of Science ®Google Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53.
   PubMed Web of Science ®Google Scholar
• Fujihara A, Ukimura O, Honjo H, et al. Urge perception index of bladder hypersensitivity. J Urol. 2013;189(5):1797–1803.
   PubMed Web of Science ®Google Scholar
• Haylen BT, Chetty N, Logan V, et al. Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity? Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:123–128.
   PubMedGoogle Scholar
• Blanco ZE, Lilue M, Palacios S. Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies. DIC. 2020;9:1–6.
   Google Scholar
• Rai BP, Cody JD, Alhasso A, et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12:CD003193.
   PubMedGoogle Scholar
• Hextall A, Cardozo L. The role of estrogen supplementation in lower urinary tract dysfunction. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12(4):258–261.
   PubMed Web of Science ®Google Scholar
• Yoshida J, Aikawa K, Yoshimura Y, et al. The effects of ovariectomy and estrogen replacement on acetylcholine release from nerve fibres and passive stretch-induced acetylcholine release in female rat bladder. Neurourol. Urodyn. 2007;26(7):1050–1055.
   PubMed Web of Science ®Google Scholar